Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer? Comment

首页> 外文期刊>The lancet oncology >Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer? Comment

【24h】

Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer? Comment

机译：免疫检查点抑制剂加抗HER2治疗：HES2阳性卵囊癌的新标准吗？评论

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2020年第6期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer? Comment [J] . The lancet oncology . 2020,第6期

机译：免疫检查点抑制剂加抗HER2治疗：HES2阳性卵囊癌的新标准吗？评论
2. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy [J] . Hou Yanjun, Nitta Hiroaki, Wei Lai, Clinical breast cancer . 2018,第2期

机译：在HER2阳性乳腺癌中使用多重免疫组织化学的免疫反应和PD-L1表达的评价：与抗HER2 Neoadjuvant治疗的反应相关性
3. Anti-HER2 CD4(+) T-Helper Type 1 Immune Response is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer [J] . De La Cruz Lucy M., McDonald Elizabeth S., Mick R., Annals of surgical oncology . 2017,第4期

机译：抗HER2CD4（+）T-辅助型1型免疫应答优于乳腺MRI，用于评估对HER2阳性乳腺癌患者的Neoadjuvant治疗的反应
4. ENGINEERING AND PRE-CLINICAL EVALUATION OF A HUMAN ENZYME IMMUNE CHECKPOINT INHIBITOR FOR CANCER THERAPY [C] . Everett Stone, John Blazek, Christos Karamitros, Enzyme Engineering Conference . 2018

机译：癌症治疗人酶免疫检查点抑制剂的工程与临床评价
5. Immune-Related Adverse Events in Cancer Patients Being Treated with Immune Checkpoint Inhibitors [D] . Byrne, Margaret M. 2021

机译：用免疫检查点抑制剂治疗癌症患者免疫相关不良事件
6. Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer [O] . Jashodeep Datta, Erik Berk, Shuwen Xu, 2015

机译：抗HER2 CD4 + T辅助1型反应是HER2阳性乳腺癌新辅助治疗后与病理反应的新型免疫相关因素
7. Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer [O] . Jashodeep Datta, Erik Berk, Shuwen Xu, 2015

机译：抗HER2 CD4 + T辅助1型反应是HER2阳性乳腺癌新辅助治疗后与病理反应的新型免疫相关因素

Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer? Comment

著录项

相似文献

相关主题

期刊订阅